All of the following are contraindications for the use of abciximab:

- Hypersensitivity to abciximab or component of the formulation

- Recent (within six weeks) clinically significant gastrointestinal (GI) or genitourinary (GU) bleeding or active internal hemorrhage

- Within two years of cerebrovascular accident or with substantial neurological deficit

- Clotting abnormalities or within seven days of administration of oral anticoagulants unless prothrombin time (PT) is 1.2 times control PT value or lower

- Thrombocytopenia (less than 100,000 cells/microliter)

- Within six weeks of major surgery or trauma

- Intracranial tumor

- Arteriovenous malformation or an aneurysm

- Severe uncontrolled hypertension

- History of vasculitis

- Use of dextran before PTCA or intent to use dextran during PTCA

- Concomitant use of another parenteral GP IIb/IIIa inhibitor

- Oral anticoagulant use within the last seven days unless a PT time of 1.2 times the control or less

- Vasculitis: clinical or documented diagnosis

- Hypertension, severely uncontrolled

- Theoretical contraindications exist for coadministration with defibrotide and eptifibatide. Interactions may increase the risk of hemorrhage.